X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The fundings will be used to advance 7HP349 (alintegimod), its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.
Lead Product(s): Alintegimod
Therapeutic Area: Oncology Product Name: 7HP349
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: CPRIT
Deal Size: $13.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 22, 2023
Details:
DNA-based vaccine to protect against Tc infection, which was tested in preclinical models in combination with 7HP’s lead, oral immunostimulant. Results of this initial study, demonstrated that the combination therapy was effective in both prophylactic and therapeutic settings.
Lead Product(s): DNA-based Vaccine,7HP349
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 01, 2022
Details:
7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.
Lead Product(s): 7HP349
Therapeutic Area: Oncology Product Name: 7HP349
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
7HP349 is 7HP’s lead, clinical-stage integrin agonist. It is a first-in-class, orally delivered small molecule that safely and selectively activates the integrins LFA-1 and VLA-4 to augment the antigen-specific immune response.
Lead Product(s): 7HP349
Therapeutic Area: Oncology Product Name: 7HP349
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Texas Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
7HP349, an allosteric activator of integrins VLA-4 and LFA-1, used in combination with immunotherapy improve effectiveness of potentially any immunotherapeutic, including, but not limited to immune checkpoint inhibitors and infectious disease vaccines.
Lead Product(s): 7HP349,Undisclosed
Therapeutic Area: Oncology Product Name: 7HP349
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
7HP349 is designed to activate integrins, enhancing cell adhesion for stronger immune responses to vaccinations, such as those for COVID-19 and influenza, and immuno-oncology drugs, such as checkpoint inhibitors.
Lead Product(s): 7HP349
Therapeutic Area: Oncology Product Name: 7HP349
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
7 Hills Pharma’s oral small molecule integrin activators directly promote cell adhesion, which is essential for immune system activation and for strengthening antigen specific immune responses of immunotherapies.
Lead Product(s): 7HP349
Therapeutic Area: Infections and Infectious Diseases Product Name: 7HP349
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Preclinical studies reveal 7HP349 significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2. The data also suggest 7HP349 can be used as an immunostimulant for any COVID-19 vaccine and has the potential to accelerate immune system response.
Lead Product(s): 7HP349
Therapeutic Area: Infections and Infectious Diseases Product Name: 7HP349
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
7 Hills Pharma is launching an evaluation of its lead compound 7HP349, a next-generation small molecule integrin activator, as an oral adjuvant with a novel recombinant coonavirus vaccine.
Lead Product(s): 7HP349
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2020
Details:
U.S. FDA has cleared the company’s investigational new drug application for 7HP349. The FDA completed its 30-day safety review and granted approval to proceed with Phase 1 healthy volunteer study.
Lead Product(s): 7HP349
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
